Participant flow

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) · Source last updated 2025-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity

   id

   FG000

   title

   Nivolumab

2. description

   Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity

   id

   FG001

   title

   Nivolumab + Ipilimumab

3. description

   Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses

   id

   FG002

   title

   Ipilimumab

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         316

      2. group Id

         FG001

         num Subjects

         314

      3. group Id

         FG002

         num Subjects

         315

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         313

      2. group Id

         FG001

         num Subjects

         313

      3. group Id

         FG002

         num Subjects

         311

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Pre-Treatment Period

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         12

      3. group Id

         FG002

         num Subjects

         19

      type

      SUBJECT WITHDREW CONSENT

   2. reasons

      1. group Id

         FG000

         num Subjects

         120

      2. group Id

         FG001

         num Subjects

         136

      3. group Id

         FG002

         num Subjects

         58

      type

      Other Reasons

   3. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         11

      3. group Id

         FG002

         num Subjects

         6

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         175

      2. group Id

         FG001

         num Subjects

         154

      3. group Id

         FG002

         num Subjects

         228

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         313

      2. group Id

         FG001

         num Subjects

         313

      3. group Id

         FG002

         num Subjects

         311

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         313

      2. group Id

         FG001

         num Subjects

         313

      3. group Id

         FG002

         num Subjects

         311

      type

      NOT COMPLETED

   title

   Treatment Period

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice